Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus brevis SBC8803

What does the research say about Lactobacillus brevis SBC8803?

12 health outcomes synthesised

Research on Lactobacillus brevis SBC8803 spans 12 health outcomes, with the strongest evidence concentrated in skin and sleep-related areas. The largest body of research examines improved skin hydration (10 papers), though the overall evidence strength is low due to a reliance on narrative reviews and only one primary randomized controlled trial for this specific strain. No consistent effective dose has been identified across studies, and most human data come from small or indirect trials, limiting firm conclusions.

Strongest evidence: No outcome meets moderate or high evidence strength; the highest is low. Among low-strength outcomes, the evidence is most concentrated for skin hydration (10 papers, all reporting benefit, but only one direct RCT with non-significant results) and sleep quality (7 papers, but only one small direct pilot trial). For skin barrier function, a meta-analysis found a statistically significant small effect on reducing trans-epidermal water loss (pSMD = -0.50, p < 0.001) in healthy adults and psoriasis populations.

Mixed or weaker evidence: The remaining outcomes have very low evidence strength. Reduced inflammation (5 papers) and improved intestinal barrier function (5 papers) show consistent beneficial direction but rely entirely on reviews, animal/cell studies, or research on other strains. Reduced alcohol-induced liver injury (3 papers) has only preclinical evidence. For atopic dermatitis, immune function, reduced body fat (meta-analysis on 58 individuals), and reduced fatigue, effect sizes are small to moderate but derived from narrative reviews or a single small trial on a different strain.

Effective dose patterns: No effective dose is reported in any of the 12 syntheses — every outcome listed 'effectiveDose' as null. This is a critical gap across the entire evidence base for this specific strain.

Population insights: The only specific population identified is adults with mild insomnia symptoms (Athens Insomnia Scale ≥6) in a single pilot study for sleep quality. One meta-analysis for reduced body fat studied obese individuals without comorbidities (n=58). Reviews for skin outcomes mention healthy adults and middle-aged/elderly subjects. No cross-cutting pattern of a particular population benefiting most is evident.

Notable caveats: Nearly all syntheses note that many included papers are narrative reviews or studies on other probiotic strains, not Lactobacillus brevis SBC8803 directly. Only one primary RCT exists for skin hydration, and one small pilot trial for sleep. No human trials were found for inflammation, intestinal barrier function, liver function, immune function, or alcohol-induced liver injury. Statistical significance is lacking or marginal in most direct studies, and clinical significance remains unclear.

Frequently asked

  • What is Lactobacillus brevis SBC8803 good for according to research?
    Research on this strain has examined 12 health outcomes. The most studied area is skin hydration (10 papers, all reporting benefit, though evidence strength is low). Other commonly researched outcomes include sleep quality (7 papers), skin barrier function (5 papers), reduced body fat (4 papers), and reduced inflammation (5 papers). However, most evidence comes from reviews or studies using other probiotic strains, not SBC8803 itself.
  • What dose of Lactobacillus brevis SBC8803 is typically used in studies?
    No effective dose was reported in any of the 12 outcome syntheses. Across all studies included in the analysis, dosing information was consistently absent or not specified, making it impossible to identify a typical or effective dose range for this strain.
  • Does Lactobacillus brevis SBC8803 help with skin hydration?
    All 10 studies examining skin hydration reported beneficial effects, with effect sizes predominantly small to moderate. However, the highest-quality evidence — a single RCT in 126 adults — found only marginal improvements that were not statistically significant (P values 0.05–0.09). A meta-analysis including this and other strains found a moderate effect, but specificity to SBC8803 is limited.
  • Are there caveats or limitations in the research on Lactobacillus brevis SBC8803?
    Yes. Many studies in the database are narrative reviews or test other probiotic strains, not SBC8803 directly. Only one direct human trial exists for skin hydration and one small pilot for sleep quality. Several outcomes have no human data at all (e.g., liver function, alcohol-induced liver injury, immune function). No studies reported an effective dose, and statistical significance is absent or marginal in most direct evidence.
  • Who benefits most from Lactobacillus brevis SBC8803?
    Populations studied are limited. For sleep quality, one pilot trial included men aged 41–69 with mild insomnia symptoms. For reduced body fat, a meta-analysis studied obese individuals without comorbidities (n=58). Skin outcomes were studied in healthy adults and healthy middle-aged/elderly subjects. No consistent pattern of greatest benefit has emerged across outcomes.
  • Can Lactobacillus brevis SBC8803 reduce inflammation?
    All 5 studies in the database reported beneficial effects on inflammation, with predominantly moderate effect sizes. However, none directly tested SBC8803 — the only RCT used a different strain (L. plantarum TWK10), and the rest were narrative reviews. Evidence for this specific strain reducing inflammation is indirect and very low certainty.

  • Simple Slumbers

    By Unisom

    Out of Stock
    Best Price Guarantee
    Prices from Different Sellers
    Prices from Different Sellers
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $14.86
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top